Comparative Pharmacology

Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5 versus PARACAINE.

Peer-Reviewed Evidence

Differential Analysis

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% vs PARACAINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%

Local Anesthetic / Antiarrhythmic (Class Ib)

Category A/B

PARACAINE

Local Anesthetic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting phase 0 depolarization and decreasing automaticity in ventricular myocardial cells. It also has local anesthetic properties by blocking nerve impulse conduction.

Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.

Clinical Dosing

Intravenous infusion: 1-4 mg/min (0.25-1 mL/min of 0.4% solution) after a loading dose of 1-1.5 mg/kg IV bolus for ventricular arrhythmias. Maximum total dose: 3 mg/kg.

10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.

Direct Interaction

None Documented

Half-Life

Terminal elimination half-life is approximately 1.5-2 hours (mean 1.8 h) in healthy adults. In patients with hepatic impairment or heart failure, half-life may be prolonged to >3 hours. In neonates, half-life can be 3-6 hours.

Other Significant Interactions

Clinical Note

moderate

Proparacaine + Fluticasone propionate

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."

Clinical Note

moderate

Proparacaine + Clemastine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."

Clinical Note

moderate

Proparacaine + Venlafaxine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."

Clinical Note

moderate